Suppr超能文献

重金属(砷、铅和汞)螯合治疗:保护还是危险?

Chelation for heavy metals (arsenic, lead, and mercury): protective or perilous?

机构信息

Division of Clinical Pharmacology & Toxicology, Department of Medicine, University of Colorado Denver, Denver, Colorado, USA.

出版信息

Clin Pharmacol Ther. 2010 Sep;88(3):412-5. doi: 10.1038/clpt.2010.132. Epub 2010 Jul 21.

Abstract

Despite clinical experience that spans more than half a century, chelation for toxic heavy metals represents one of the most controversial and misapplied interventions in clinical toxicology. The prompt use of chelating agents to treat acute, life-threatening intoxication is an indication that is largely supported by experimental animal data and limited clinical research. Although chelating agents administered for chronic intoxication may accelerate the excretion of heavy metals, their therapeutic efficacy in terms of decreased morbidity and mortality is largely unestablished. Recent investigations suggest that their use in such settings might be associated with deleterious effects. Careful attention to risk-benefit issues is warranted, particularly in clinical situations in which the etiological role of heavy metals in the patient's illness is in question.

摘要

尽管临床经验已有半个多世纪,但螯合疗法治疗有毒重金属仍然是临床毒理学中最具争议和误用的干预措施之一。及时使用螯合剂治疗急性、危及生命的中毒是一种主要基于实验动物数据和有限的临床研究的适应症。虽然用于慢性中毒的螯合剂可能会加速重金属的排泄,但它们在降低发病率和死亡率方面的治疗效果在很大程度上尚未确定。最近的研究表明,在这种情况下使用它们可能与有害影响有关。需要仔细关注风险效益问题,特别是在重金属在患者疾病中的病因作用存在疑问的临床情况下。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验